奈良宣言（ALT over 30）のMASLD（metabolic dysfunction-associated steatotic liver disease）における臨床的意義の検証

DOI Web Site Web Site 参考文献4件 オープンアクセス

書誌事項

タイトル別名
  • Importance of ALT levels of >30 in patients with MASLD: Nara Declaration 2023
  • ナラ センゲン(ALT over 30)ノ MASLD (metabolic dysfunction-associated steatotic liver disease)ニ オケル リンショウテキ イギ ノ ケンショウ

この論文をさがす

説明

<p>The Nara Declaration 2023 recommends that patients with ALT levels of >30 U/L and those who have steatosis, diabetes, hypertension, and/or dyslipidemia should be referred to a hepatologist, considering the results of the FIB4 index and/or platelet count. ALT levels of >30 U/L is a simple and useful indicator and, when combined with the FIB4 index and platelet count, can detect MASLD cases that require further treatment and follow-up. Moreover, among patients with MAFLD and ALT levels of ≤30 U/L, the FIB4 index may be useful for identifying those at risk of MASLD. The Nara Declaration 2023 is an important and convenient guideline that provides primary care doctors with specific indications for referral to a hepatologist. When combined with the FIB4 index, ALT levels of >30 U/L is expected to predict high-risk MASLD cases.</p>

収録刊行物

  • 肝臓

    肝臓 65 (4), 186-191, 2024-04-01

    一般社団法人　日本肝臓学会

参考文献 (4)*注記

もっと見る

キーワード

詳細情報 詳細情報について

問題の指摘

ページトップへ